ICU Medical (NASDAQ:ICUI) Upgraded to “Strong-Buy” at BTIG Research

ICU Medical (NASDAQ:ICUI) was upgraded by research analysts at BTIG Research to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

ICUI has been the topic of a number of other reports. Piper Sandler reduced their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. KeyCorp cut their target price on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Weiss Ratings raised shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 27th. Three investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $168.40.

ICU Medical Price Performance

ICU Medical stock opened at $143.72 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. ICU Medical has a 52 week low of $107.00 and a 52 week high of $160.29. The stock has a market capitalization of $3.59 billion, a P/E ratio of 77.69, a price-to-earnings-growth ratio of 1.99 and a beta of 0.77. The stock has a fifty day moving average of $128.53 and a 200-day moving average of $138.66.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.19. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. During the same period last year, the firm posted $1.72 earnings per share. ICU Medical’s revenue was down 12.3% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, sell-side analysts expect that ICU Medical will post 6.5 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Large investors have recently modified their holdings of the business. Hilton Head Capital Partners LLC acquired a new position in shares of ICU Medical during the fourth quarter worth $32,000. Covestor Ltd increased its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock valued at $99,000 after purchasing an additional 126 shares during the period. Strs Ohio increased its holdings in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares during the period. Rockefeller Capital Management L.P. raised its position in ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in ICU Medical during the 4th quarter worth $120,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.